

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO. FILING DATE 09/623,970 12/28/2000		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
		Isao Karube	201487/1030			
75	, 590 05/07/2002					
Michael L Goldman			EXAMINER			
Nixon Peabody Clinton Square			LOEB, BRONWEN			
PO Box 31051 Rochester, NY	14603		ART UNIT	PAPER NUMBER		
,			1636	14		
			DATE MAILED: 05/07/2002			

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Application	Application No.		Applicant(s)				
		09/623,9	/623,970 KARUBE ET AL.						
		Examiner			Art Unit				
		Bronwen	M. Loel	0	1636	_			
Period fo	The MAILING DATE of this communication a or Reply	ppears on the	e c vei	sheet with the c	orrespondence ac	ldress			
THE - Exte after - If the - If NO - Failu - Any	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. a period for reply specified above is less than thirty (30) days, a red period for reply is specified above, the maximum statutory period reto reply within the set or extended period for reply will, by statute to reply within the set or extended period for reply will, by statutely received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	I. 1.136(a). In no eveply within the stated will apply and wute, cause the app	ent, howe utory min ill expire a lication to	ever, may a reply be tim imum of thirty (30) day: SIX (6) MONTHS from b become ABANDONE	nely filed s will be considered time the mailing date of this o O (35 U.S.C. § 133).				
1)⊠	Responsive to communication(s) filed on 14	4 February 20	<u> 202</u> .						
2a)⊠	This action is FINAL . 2b)	This action is	non-fi	nal.					
3)□	Since this application is in condition for allow closed in accordance with the practice under					ne merits is			
·	ion of Claims								
4) Claim(s) 1 and 6-24 is/are pending in the application.									
	4a) Of the above claim(s) <u>7-20</u> is/are withdrawn from consideration.								
	5) Claim(s) is/are allowed.								
6)⊠	Claim(s) 1, 6 and 21-24 is/are rejected.								
7)니	Claim(s) is/are objected to.		•						
8)∐(8	Claim(s) are subject to restriction and ion Papers	l/or election r	equire	ment.					
	The specification is objected to by the Examir	ner							
·	The drawing(s) filed on <u>28 December 2000</u> is.		cented	or b) Objected t	o by the Evamine	ar.			
10)[Applicant may not request that any objection to				-				
11)	• • • • • • • • • • • • • • • • • • • •								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
<i>,</i> —	under 35 U.S.C. §§ 119 and 120								
	**	ian priority ur	ider 35	5 II S C 8 119(a)-(d) or (f)				
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)⊡ Some * c)⊡ None of:									
a)⊠ All b) Some c) None or: 1. Certified copies of the priority documents have been received.									
	Certified copies of the priority documents have been received in Application No Certified copies of the priority documents have been received in Application No								
	3. ☐ Copies of the certified copies of the pri					Stono			
* 5	application from the International E See the attached detailed Office action for a li	Bureau (PCT	Rule 1	17.2(a)).		Stage			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).									
) The translation of the foreign language p Acknowledgment is made of a claim for dome	•	•						
Attachmen	-	•		30					
2) Notic	ce of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s))	4)		(PTO-413) Paper No Patent Application (PT				

Art Unit: 1636

DETAILED ACTION

This action is in response to the amendment of 14 February 2002 in which claims 2-5 were cancelled and new claims 21-24 were presented.

Claims 1 and 6-24 are pending.

Election/Restrictions

- 1. Claims 7-20 are withdrawn from further consideration pursuant to 37 CFR

 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 9.
- 2. This application contains claims 7-20 drawn to an invention nonelected with traverse in Paper No. 9. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Response to Amendment

3. The rejection of claims 1-6 under 35 USC §112, second paragraph as being indefinite has been withdrawn in view of Applicant's amendment.

The rejection of claims 1-6 under 35 USC §102(b) as being anticipated by Thorpe et al (Biophysical J. (1995) 68:2198-2206) has been withdrawn in view of Applicant's amendment.

Art Unit: 1636

The rejection of claims 1-6 under 35 USC §102(b) as being anticipated by Valenzeno (Photochemistry and Photobiology (1987) 46:147-160) has been withdrawn in view of Applicant's amendment.

The rejection of claims 2-4 under 35 USC §102(b) as being anticipated by Morgan (GB 2 209 468 A) has been withdrawn in view of Applicant's amendment.

The rejection of claims 1-4 under 35 USC §102(b) as being anticipated by Sambrook et al (Molecular Cloning, A Laboratory Manual (1989) Cold Spring Harbor: Cold Spring Harbor Laboratory Press, pages 16.30-16.31 and 16.48-16.53) has been withdrawn in view of Applicant's amendment.

The declarations under 37 CFR 1.132 filed 14 February 2002 are sufficient to overcome the rejection of claims 1-5 based upon Saito et al ((Photochemistry and Photobiology (1998) 68:745-748).

The declaration under 37 CFR 1.132 filed 14 February 2002 is sufficient to overcome the rejection of claims 1-6 based upon insufficiency of the disclosure under 35 USC §112, first paragraph.

4. Claims 1, and new claims 21-24, stand rejected under 35 USC §112, first paragraph for insufficient written description for reasons of record and as further discussed below.

Claims 1, 6 and new claims 21-24, stand rejected under 35 USC §102(b) as being anticipated by Morgan (GB 2 209 468 A).

Art Unit: 1636

Response to Arguments

5. With respect to the rejection of claims 1, and new claims 21-24, stand rejected under 35 USC §112, first paragraph for insufficient written description, Applicant's arguments have been fully considered but are deemed not persuasive.

Applicant argues that the elements recited in claim 1 are fully described in the specification. This is not persuasive as the issue is not simply the individual agents or stimuli disclosed in the specification but the operable combinations of them. The number of possible combinations of agent and stimulus is extremely large. For instance, the specification teaches 9 types of stimulus and 11 types of agents. This yields 99 combinations to be tested. The specification further teaches that combinations of the agents and/or the stimuli may also be used. If one is to combine two stimuli, there are 36 possible combinations of stimuli. Two stimuli combinations times one of the 11 agents yields 396 combinations to be tested. If one is to combine two agents, there are 57 possible combinations of agents. Two agent combinations times one of the 9 stimuli yields 513 combinations to be tested. Two agent combinations times two stimuli combinations yields 2052 combinations to be tested. This sums to 3060 individual combinations that need to be tested. It is important to further note that each of the nine stimuli and 11 agents are in fact classes; for instance photosensitizers is one of the stimulus. There are 5 photosensitizers disclosed in the specification; it is likely there are many more. It is also important to note that for each combination, one will have to test a series of concentrations of agent and degrees of stimulation. Thus the numbers of combinations to be tested calculated above is actually

Art Unit: 1636

a very low underestimate when one considers the actual number of specific agents and specific stimuli taught by the specification and encompassed by the claims, as well as the series of concentrations and degrees of stimulation one would have to test within a given combination. Furthermore, the specification provides no specific guidance on what combinations are most likely to be operable or what concentrations and degrees of stimulus exposure will most likely be operable. There is only one species disclosed, terthiophene (BAT) and argon laser light. This single species is not a representative number for the number of species encompassed by the genus. The rejection is maintained.

6. With respect to the rejection of claims 1, 6 and new claims 21-24, under 35 USC §102(b) as being anticipated by Morgan (GB 2 209 468 A), Applicant's arguments have been fully considered but are deemed not persuasive.

Applicant argues that the technique taught by Morgan works only in liposomes and only when the liposomes are the same material as the membrane to be disrupted whereas the instant invention is not so constrained. This is not persuasive because it is unclear where in Morgan either of the above assertions is demonstrated. Furthermore, Morgan clearly teaches using liposomes comprising a photosensitizing agent (thus the membrane-disrupting agent is attached to a support) to fuse with cells or tissues when the liposomes contact the cells or tissues and are exposed to irradiation. As set forth in the previous action, the fusion of the liposomes to the cells indicate that there is a specific site of perforation of denaturation in the liposome. The teachings of Morgan disclose a species which thus anticipates the genus encompasses by the claims.

Furthermore, the pending claims do not exclude liposomes as supports. The rejection is maintained.

Conclusion

Claims 1, 6 and 21-24 are rejected.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Certain papers related to this application may be submitted to Art Unit 1636 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone numbers for the Group are (703) 308-4242 and (703) 305-3014. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bronwen M. Loeb whose telephone number is (703) 605-1197. The examiner can normally be reached on Monday through Friday, from

Art Unit: 1636

10:00 AM to 6:30 PM. A phone message left at this number will be responded to as soon as possible (usually no later than the next business day after receipt by the examiner).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Dr. Remy Yucel, can be reached on (703) 305-1998.

Any inquiry of a general nature or relating to the status of this application should be directed to Tracey Johnson, Patent Analyst whose telephone number is (703) 305-2982.

Bronwen M. Loeb, Ph.D. Patent Examiner Art Unit 1636

May 5, 2002

DAVID GUZO PRIMARY EXAMINER